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The research involving tissue factors, such as granulocyte
macrophage colonies stimulating factor (GM-CSF) and interleukin
5 (IL-5), leads to the mechanisms involved in the maintenance of
eosinophilia, which is essential for the pathogenesis on eosinophilic
nasal polyps. Mitomycin C has been successfully used in
otolaryngology. Aim: The objective of this study was to evaluate
the effect of mitomycin C in secretion of GM-CSF and IL-5 on
eosinophilic nasal polyps. Study design: case-control. Material
and Method: This is a comparative and auto-matched experimental
study, performed with fragments of polyps which had been
obtained from biopsy of patients with eosinophilic nasosinusal
polyposis. The fragments of the experimental group were treated
with mitomycin C (400 microg/ml) for 5 minutes and then washed
in RPMI substrate. At time zero, 12 and 24 hours, the surface
material was taken to determination of its GM-CSF levels in 22
patients and of IL-5 levels in 19 patients, by ELISA method. Results:
Reduction in GM-CSF expression on the experimental group at
time 24 h (p<= 0.05). The treated group presented significant GM-
CSF expression between zero time and 12 h time (p=0.013) showing
the culture viability such as in the non-treated group. Tendency to
decreasing IL-5 levels on the treated groups at 24 hours.
Conclusion: This study showed that mitomycin C was efficient in
inhibiting GM-CSF synthesis with reduction of IL-5 secretion, but
this fact needs complementary studies.
Key words: polyposis, nasal, eosinophil,
GM-CSF, IL-5, mytomicin C.
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INTRODUCTION
Nasosinusal polyposis - NSP results from a chronic
inflammatory process of the nasosinusal mucosa, with
different stages of nasosinusal cavity impairment.
Eosinophilic NSP represents 80 to 90% of NSP, associated
with nasal and/or bronchial hyperreactivity and responds
well to corticotherapy. It involves patients with different
etiological factors and clinical evolution relative to upper
and lower airways. Eosinophilic NSP is found in Nonallergic
rhinitis with eosinophilia syndrome (NARES), in Fernand-
Widal syndrome, atopia, allergic fungal sinusitis and Churg
Strauss syndrome. NSP affects adult subjects with
prevalence of 1 to 4% of the population and it is frequently
increase in view of the concomitance with non-allergic
bronchial asthma, reaching peaks at about 40 years of
age.1,2
Treatments of choice for this affection are: use of
corticoids, that act in the reduction of the inflammatory
process determined by the eosinophils, and surgical
treatment. Surgical indication is reserved for cases that
demonstrate a significant obstruction of nasal cavities or those
associated with recurrent infections of nasosinusal mucosa.
Despite the relevant advances in basic research, little has
progressed in therapeutic terms. The rate of recurrence is
high, even after a surgical procedure.
The study of GM-CSF and IL-5 is justified by the fact
that they are extremely important cytokines for differentiation,
migration, capture, activation and survival of eosinophils. They
are produced by eosinophils in high amounts in the
inflammatory sites, resulting in a self-sustainable cycle of
stimulation. Such cytokines, associated with eosinophils,
acquire a key role in the pathophysiology of eosinophilic
NSP. 2-6
The use of MMC is extremely important because it is
an antineoblastic and antibiotic drug that acts as an alkylating
agent, inhibiting DNA, protein synthesis and fibroblasts in
cell cultures. MMC has been experimentally used in the
prevention of stenosis in maxillary antrostomies, glaucoma
surgery and pterygiums, in myringotomy and in laryngeal
stenosis.7-10
The purpose of the present study was to assess the
action of Mitomycin C over the synthesis of the granulocyte
macrophage colony stimulating factor (GM-CSF) and
interleukin 5 (IL-5).
MATERIAL AND METHOD
The studied population was formed by patients with
extensive NSP, aged between 16 and 79 years, referred by
SUS (Universal Healthcare System in Brazil), to perform
surgical treatment at Hospital Sao Geraldo, a unit of Hospi-
tal das Clínicas, Federal University of Minas Gerais - HC-
UFMG.
We selected 22 patients with eosinophilic NSP, with
eosinophil percentage equal or greater than 40% 11, in the
period between January and June 2003. Patients with non-
eosinophilic polyposis such as cystic fibrosis, Kartagener
syndrome, antro-choanal polyp or eosinophilic NSP with
active infection were excluded from the study.
Selected patients were submitted to complete ENT
examination, special attention to the nasal segment. Na-
sal fossa was explored via anterior rhinoscopy and
fibronasolaryngoscopy.
We carried out an experimental comparative self-
matched study with 22 samples of eosinophil polyps. The
studied group comprised culture by fragment of polyps
treated with MMS and assessed at zero, 12 and 24 hours for
each patient. The control group comprised culture of
fragments of polyps not treated with MMC and assessed at
the same hours.
We carried out biopsy of nasal polyps both for
characterization of eosinophilia and cultures. The fragments
obtained for eosinophilic assessment were immediately fixed
with formol at 10% and referred to histopathological exam
with hematoxylin-eosin (HE). Findings of at least 40% of
eosinophils in inflammatory cells and/or presence of at least
four eosinophils per four microscopic fields of magnification
were considered eosinophilia 11.
Biopsies of nasal polyps obtained for culture were made
in the ambulatory of Otorhinolaryngology, HC-UFMG.
Removed fragments were immediately placed in a culture at
room temperature. Fragments were sectioned in three
portions of 3mm3 and grew in a plate with 6 orifices containing
0.5ml RPMI medium. Among the six compartments, three
formed the experimental group and three the control group.
In the experimental group we applied MMC for 5 minutes, at
dosage of 400 µg/ml.9 After the application of the drug, cultures
were rinsed in RPMI medium. To the control group, not treated
with MMC, we made the same manipulation only with RPMI
medium. Fragments and culture media were placed in the
first compartments, control and experiment were immediately
frozen for later use with the method Enzyme Linked Immu-
nosorbent Assay (ELISA). The other two pairs of samples,
both containing control and experiment, were incubated for
12 and 24 hours, respectively, in hot oven at 37o C and 0.5%
CO
2 
up to the moment of collection and freezing.
The used medium of culture was RPMI 1640,
commercialized by Gibco UK, containing 5% human serum
AB, 2 m M mercaptoethanol, 1 mM L-glutamin, 2mM sodium
piruvate, 10m gr/ml streptomycin, 100U/ml penicillin and
5mg/ml fungisone.12
At zero, 12 and 24 hours, cultures were preserved at
80o C temperature up to the moment of the analysis. After
defrosting at room temperature, cultures were centrifuged
at 3o C during 10 minutes at 15,000 rpm.12 Supernatants
were submitted to ELISA method to determine the levels of
GM-CSF and IL5. Kits R&D Systems: Duoset® Human GM-
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CSF / Catalog: DY215; Duoset® Human IL-5 Catalog:
DY205.12 Out of biopsied patients, 22 were submitted to
analysis for quantification of GM-CSF and 19 for IL-5.
The method used for statistical analysis was the t paired
test to compare the groups in each one of the times,
according to Snedecor and Cochran (1977).13 We considered
the level of significance of 5% and we used the statistical
package Minitab, version 13, for statistical data analysis.
The study was previously approved by the Research
Ethics Committee, UFMG.
RESULTS
Out of 22 studied experiments to determine the levels
of GM-CSF, in three of them we did not reach enough size
for the culture at hour 24, and in 19 of them experiments
were assessed at this time.
Figure 1 demonstrates the expression of GM-CSF in
cultures. We could observe that at zero hour, cultures, with
or without MMC, did not present statistical difference between
the two groups (p= 0.362). At hour 12, the behavior of the
curve revealed that the group that received MMC presented
lower levels of GM-CSF in relation to the control group, but
there was no statistically significant difference (p= 0.570).
At 24 hours, the curve showed statistically significant
difference between the two groups (p £ 0.05).
Assessing separately the expression of GM-CSF in the
two experiments, we observed that in the group without
MMC, between zero and 12 hours, there was no statistically
significant difference (p= 0.087). Between zero and 24 hours,
there was statistically significant difference (p= 0.048). There
was no statistically significant difference between hour 12
and hour 24 (p= 0.409), even though at hour 24 we had
reached the same levels of GM-CSF.
Similarly, analyzing the group with MMC application,
we observed similar behavior, with statistically significant
differences for zero and 12 hours (p= 0.013) and borderline
between zero and 24 hours (p= 0.068), and we did not
observe statistically significant difference in the comparison
between 12 and 24 hours (p= 0.606), even though levels of
GM-CSF had been higher than 24 hours.
Figure 2 shows the expression of IL-5 in the studied
cultures. Out of 19 experiments, two did not reach enough
size for culture of 24 hours, and only 17 experiments were
assessed at this time.
When compared at zero hour, we observed that there
was no statistically significant difference between the groups
(p= 0.362). The curve shows greater expression of IL-5 in
the group treated with MMC, but this difference was not
significant in 12 hours (p= 0.281), with clear drop in levels
of IL-5 as of this time. Conversely, control cultures that were
not treated with MMC had growing expression of IL-5, and
we did not observe any significant difference between the
two groups at 24 hours (p= 0.105).
Upon analyzing the two groups separately, we
observed that in MMC cultures, there was statistically
significant difference in expression of IL-5 between zero
and 12 hours (p= 0.046), and between zero and 24 hours
(p= 0.027). Between 12 and 24 hours, there was no
statistically significant difference (p= 0.671). In the cultures
treated with MMC, we did not find any significant difference
between zero and 12 hours (p= 0114), zero and 24 hours
(p= 0.635), as well as between 12 and 24 hours (p= 0.112).
DISCUSSION
The study of eosinophil physiology has demonstrated
that these cells perform an essential role in the allergic
inflammatory and anti-parasitic response, presenting the
capacity to interact with other cells through specific receptors.
They are extremely versatile and produce a wide range of
substances capable of causing tissue lesion and others that
may expand and perpetuate the inflammatory response.14
Figure 2. Curves of expression of IL-5, with and without application of
MMC.
Figure 1. Curves of GM-CSF expression, with and without application
of MMC.
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Eosinophils have serum half-life of approximately 18
hours, but they can remain for weeks in the tissues,
depending on environmental stimuli 15. Small eosinophilic
grains are responsible for the accumulation of toxic
substances, such as major basic proteins (MBP), eosinophilic
cationic proteins (ECP) and eosinophilic peroxidase (EPO).
They are involved in the cytotoxicity against parasites and
tissues, such as we find in bronchial asthma, urticaria and
eosinophilic NSP. 16
Cara, Negrão-Corrêa and Teixeira (2000)14 made
an excellent review about the physiology of eosinophils.
According to the authors, eosinophils express receptors
to many different molecules, such as: immunoglobulins
(IgG, IgE, IgA), complement (C1q, C3b/C4b, iC3b, C5a),
kemokines (eotaxin, eotaxin-2, RANTES, MCP-3, MCP-
4), cytokines (IL-3, IL-5 and GM-CSF), lipid mediators
(PAF, LTB
4 
) and finally steroids (estrogen and
glucocorticoids). Through these receptors, eosinophils
may interact with the environment. In addition to these
receptors, there are also clustering determining antigens
(ADA), among which we can include cell adhesion
molecules CD11/CD18, VLA-4,(±4²1), ±4²7 and CD62L
(L-selectin).
In the last decade, eosinophils have been related to
eosinophilic inflammatory diseases and there was no
significant difference between pathologic processes of
eosinophilia in NSP, intrinsic or extrinsic asthma. In many
different studies, eosinophils are considered the main cells
involved in the genesis of these diseases.5,6 Thus, in these
studies, we considered to be value any type of eosinophilic
NSP, and there was no distinction among the studied cases.
Kramer et al. (2000)17 suggested that the mechanisms
involved in the genesis of eosinophilic polyposis, of allergic
origin or not, are similar.
Clutterbuck, Hirst and Sanderson (1989)18, using
recombining IL-5, IL-3 and GM-CSF in human bone marrow
cultures observed that IL5 stimulates specifically the
differentiation of eosinophils, without influencing other
lineages such as eosinophils/basophils or eosinophils/
erythrocytes. IL-3 and GM-CSF in high concentration, both
stimulate the eosinophil colony such as netrophils and mixed
colonies of eosinophils and granulocyte macrophage. Working
together, IL-5, IL-3 and GM-CSF present an additive and non-
synergetic effect, even in low concentrations of IL3 and GM-
CSF.
According to Sanderson (1992)19, IL-5 is important
and specific in the differentiation of eosinophils. In the same
manner, the author has genetically manipulated mice,
managing to have a line with increase in production of IL-5
and findings of hyper-eosinophilia. The opposite experience
was developed by Foster et al. (1996)20 and Kopf et al.
(1996)21, in which the line of mice with low level of IL5
resulted in hypo-eosinophilia, even after stimulation with
allergens. It is known that both isolated or in synergism with
IL-5, eotaxin is capable of releasing eosinophils from the
bone marrow to the blood stream.22
Lacy and Moqbel (1997)23 concluded that the
importance of the synthesis of GM-CSF for eosinophils resi-
des in autocrine and paracrine actions, capable of activating
and prolonging the survival of their own in vivo eosinophils.
MMC is an alkylating antiblastic agent discovered by
Hata et al. (1956)24 and it acts in the inhibition of DNA
synthesis.25 It was capable of inducing apoptosis in gastric
tumor cells.26 Kim et al. (1999)27 observed that MMC (0.4
mg/ml for five minutes) induced in vitro apoptosis of human
fibroblasts in Tenon capsule.
ELISA test has shown high sensitivity and specificity
in many different studies involving eosinophilic NSP with
IL-5 and GM-CSF investigation.2-4,17
The results obtained in this assay showed that the
levels of GM-CSF were significantly lower in the cultures
treated with MMC within 24 hours, (p£ 0.05). Probably, owing
to size of the involved sample (n=22), it was not possible to
detect significant difference within 12 hours, but owing to
higher accumulation of cytokines within 24 hours, we found
statistically significant difference between zero and 12 hours
(p= 0.013) and borderline between zero and 24 (p= 0.068)
for cultures treated with MMC.
In the group not treated with MMC, there was the
same pattern of accumulation, with statistical difference
between zero and 24 hours (p= 0.048). It was not possible
to detect a statistically significant difference between 12
and 24 hours in both groups (p= 0.606 - with MMC) and (p=
0.409 - without MMC), probably owing to size of sample
involved (n= 19), which was not expressive enough for
statistical detection in these times. These results are in
agreement with the literature, which demonstrates reduction
of the expression of GM-CSF when using corticosteroids in
eosinophilic NSP.28-30
The results of the action of MMC in IL-5 synthesis did
not detect any significant difference between the two groups,
with or without MMC treatment in times zero, 12 and 24
hours. The p values were: p= 0.362, p= 0.281 and p= 0.105,
respectively.
Upon observing the curve of IL-5 secretion only in
the group treated with MMC, we detected higher initial
production of cytokine at 12 hours and sudden drop at 24
hours. In this same groups, owing to large variation of results,
with large standard deviation, we did not observe difference
between times zero and 12 hours (p= 0.114), zero and 24
hours (p= 0.635) and 12 and 24 hours (p= 0.112). In Figure
2, we observed that the levels of secretion IL5 quickly drop
between 12 and 24 hours, which suggests an action of the
drug in this group.
As to IL-5, we did not observe the action of MMC as
expected in the objectives, even with tendency to reduction
of levels of cytokines (Figure 2). However, given that there
was no previous control of size of samples, we could not
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conclude that MMC has had no action over IL-5 secretion,
requiring further study.
The non-treated group with MMC proved to be more
homogenous, with similar results to those found in GM-CSF
study. There were statistically significant differences between
zero and 12 hours (p= 0.046) and between zero and 24
hours (p= 0.027). We did not observe statistically significant
difference between 12 and 24 hours (p= 0.671), probably
owing to lack of nutrients in the culture. We observed that
the cultures remained viable, with growing production of
IL-5.
CONCLUSION
The data in the present study show that mitomycin C
was capable of significantly inhibiting the synthesis of GM-
CSF. Data obtained in expression of IL-5 indicate a strong
tendency to the reduction of this cytokine induced by
mitomycin C.
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